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Abstract
Background Many therapeutic options are available to glaucoma patients. One recent therapeutic option is minimally
invasive glaucoma surgical (MIGS) devices. It is unclear how patients view different treatments and which patient-reported
outcomes would be most relevant in patients with mild to moderate glaucoma. We developed a questionnaire for patients
eligible for MIGS devices and a patient preference study to examine the value patients place on certain outcomes associated
with glaucoma and its therapies.
Objectives To summarize the progress to date.
Methods Questionnaire development: We drafted the questionnaire items based on input from one physician and four patient
focus groups, and a review of the literature. We tested item clarity with six cognitive interviews. These items were further reﬁned.
Patient preference study: We identiﬁed important beneﬁt and risk outcomes qualitatively using semi-structured, one-on-one
interviews with patients who were eligible for MIGS devices. We then prioritized these outcomes quantitatively using best-worst
scaling methods.
Results Questionnaire testing: Three concepts were deemed relevant for the questionnaire: functional limitations, symptoms,
and psychosocial factors. We will evaluate the reliability and validity of the 52-item draft questionnaire in an upcoming ﬁeld test.
Patient preference study: We identiﬁed 13 outcomes that participants perceived as important. Outcomes with the largest relative
importance weights were “adequate IOP control” and “drive a car during the day.”
Conclusions Patients have the potential to steer clinical research towards outcomes that are important to them. Incorporating
patients’ perspectives into the MIGS device development and evaluation process may expedite innovation and availability of
these devices.
Introduction
Recent innovation in glaucoma procedures has led to the
development and application of minimally invasive glaucoma
surgical (MIGS) devices. The U.S. Food and Drug Admin-
istration (FDA) approved the ﬁrst MIGS device in June 2012
[1]. FDA in collaboration with the American Glaucoma
Society (AGS) held a Workshop on “Supporting Innovation
* Tianjing Li
tianjing.li@cuanschutz.edu
1 Department of Ophthalmology, School of Medicine, University of
Colorado Denver, Aurora, CO, USA
2 Department of Epidemiology, Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD, USA
3 Department of Medicine, University of California, Los Angeles,
CA, USA
4 Scheie Eye Institute, University of Pennsylvania,
Philadelphia, PA, USA
5 Ofﬁce of Ophthalmic, Anesthesia, Respiratory, ENT and Dental
Devices, Center for Devices and Radiological Health, United
States Food and Drug Administration, White Oak, MD, USA
6 Wills Eye Hospital, Sidney Kimmel School of Medicine, Thomas
Jefferson University, Philadelphia, PA, USA
7 Ofﬁce of Strategic Partnerships and Technology Innovation,
Center for Devices and Radiological Health, United States Food
and Drug Administration, White Oak, MD, USA
8 Stanford University School of Medicine, Stanford, CA, USA
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
for Safe and Effective Minimally Invasive Glaucoma
Surgery” in February 2014 [2]. Discussions at the workshop
formed a foundation of a leapfrog MIGS Guidance [3]. It was
also recognized that evaluation of glaucoma devices had
included very little input from patients prior to 2015. Thus,
the essential next step for MIGS innovation was incorporation
of patient voice.
The past decade, perhaps more than any other period in
history, has seen a trend away from the paternalistic approach
to healthcare where physicians often decided and conveyed
what they thought was best for patients without the patients
having a voice in the decision-making process. Health
care systems are increasingly incorporating patient-reported
outcome measures to ensure that therapeutic and diagnostic
approaches are informed by patients’ perspectives [4].
Payers are more likely to make favorable coverage decisions
for products and procedures that are supported by scientiﬁc
information obtained from patients. FDA has encouraged
and, more recently, issued guidance on patient-reported
outcomes and patient preference information to accompany
traditional study ﬁndings relating to safety and effectiveness
endpoints as part of medical device submissions [5, 6].
Patient input can be incorporated into the development,
evaluation, and labeling of medical products [6–9].
Health-related quality of life, one type of patient-reported
outcome, refers to what patients can do (functioning) and
how they feel (well-being) in physical, mental, and social
health domains of life [10]. Health-related quality of
life domains may include physical functioning, role
functioning, social functioning, depressive symptoms,
anxiety, anger, positive affect, pain, energy, and general
health perceptions. FDA deﬁnes patient preference infor-
mation as “qualitative or quantitative assessments of the
relative desirability or acceptability to patients of speciﬁed
alternatives or choices among outcomes or other attributes
that differ among alternative health interventions” [6].
Preference information reﬂects the value that patients place
on beneﬁts and risks of therapies. Thus, patients’ pre-
ferences provide context grounded in information provided
by patients to prioritize outcomes. Patient preference
information is particularly useful when there are many
treatment options available, with none superior for all
patients; patients’ views about the most important beneﬁts
and acceptable risks vary considerably or differ from those
of health care professionals; and when the evidence sup-
porting one option over others is uncertain [11].
To facilitate the incorporation of patients’ input on glau-
coma devices, we formed a consortium of FDA, Centers of
Excellence in Regulatory Science and Innovation (CERSIs) at
Johns Hopkins University and University of California San
Francisco (UCSF)/Stanford, and the AGS. FDA funded the
UCSF/Stanford CERSI to develop a patient-reported outcome
instrument targeting patient with mild to moderate open angle
glaucoma (OAG) eligible for MIGS devices. Concurrently,
FDA funded the Johns Hopkins CERSI to conduct a pre-
ference study to identify which outcomes matter most to
patients with mild to moderate OAG and that affect their risk
tolerance and perspective on beneﬁt for MIGS devices. The
objective of this paper is to summarize the background and
progress on the two projects to date.
Methods
Patient-reported Outcome Instrument Development
(Questionnaire)
The ﬁrst phase of the questionnaire development was a phy-
sician focus group conducted in conjunction with the 2016
AGS Annual Meeting. The physician focus group was fol-
lowed by four patient focus groups conducted at two academic
centers (University of California Los Angeles and the Uni-
versity of Pennsylvania) and two private practice groups in
Arkansas and Texas. Using the patient eligibility criteria from
FDA guidance documents for MIGS device clinical investi-
gations [3], we queried patients with gonioscopy-conﬁrmed
mild to moderate OAG about their symptoms, factors
important to their quality of life, and how all other aspects of
living with glaucoma have impacted their lives.
We used the information from the focus groups and a
review of the literature to draft the questionnaire items. We
tested the clarity and appropriateness of the items with six
cognitive interviews in Arkansas. This draft instrument was
subsequently reﬁned iteratively based on input at several
live and remote meetings. An AGS Committee chaired by
Dr. George Spaeth played a major role in these revisions.
To further reﬁne the questionnaire items, we conducted 19
additional cognitive interviews, ﬁve of which were conducted
face-to-face in Los Angeles. The other interviews were con-
ducted online using telecommunications applications (n= 8)
or by phone (n= 6). Based upon these cognitive interviews,
we reﬁned questions to enhance understanding among those
taking the questionnaire.
Patient preferences study
The methods for the patient preference study have been
published elsewhere and are summarized brieﬂy below
[12, 13]. To explore patients’ perspectives and experiences
living with glaucoma and to identify important beneﬁts and
risks that patients consider before electing treatments such
as MIGS devices, we ﬁrst conducted semi-structured, in-
person qualitative interviews with adult patients older than
21 years of age who were suspected or diagnosed with
ocular hypertension or mild to moderate OAG seen at the
Johns Hopkins Wilmer Eye Institute between May and
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December 2016. The interview questions focused on factors
patients consider when deciding between different treat-
ments. We used the framework method to code and analyze
the qualitative data and focused on considerations expressed
by patients that can be translated into outcomes in future
MIGS clinical trials [14].
To quantify patients’ stated preferences for glaucoma
outcomes and use this information to prioritize outcomes
that were important to them, we conducted a cross-sectional
study using best-worst scaling (BWS) methods based on
ﬁndings from the qualitative input described above [15]. We
recruited adult patients older than 21 years of age who were
suspected of or diagnosed with ocular hypertension or mild
to moderate OAG from one academic-based and three
private glaucoma clinics between September 2017 and
February 2018. We administered the survey online and
asked participants to rate the importance of outcomes on a
5-point response scale as a warm-up exercise followed by
completion of BWS tasks. For each task, we presented
participants a subset of outcomes and participants chose the
most important and least important outcomes. We analyzed
response patterns using conditional logistic regression to
determine the relative importance of the different outcomes.
Results
Patient-reported Outcome Instrument Development
(Questionnaire)
While most ophthalmologists in the physician focus group
were subspecialist members of the AGS, there were also
comprehensive ophthalmologists on the panel. The primary
specialty was glaucoma (n= 9), ophthalmology (n= 2),
and general/comprehensive (n= 1). Ten were men and two
were women. Age categories selected by participants were
31–40 years (n= 1), 41–50 (n= 6), 51–60 (n= 1), 61–70
(n= 2), and 71 or older (n= 2). Table 1 shows the concepts
of interest identiﬁed by the group.
There were 19 females and 22 males in the patient focus
groups: 16 non-Hispanic Whites, 15 African Americans, 7
Hispanics and 3 Asians. Some, but not all these patients had
undergone or were candidates for MIGS procedures.
Table 2 shows unranked concepts identiﬁed in the patient
focus groups. Activity limitation, difﬁculties with night
driving, loss of depth perception, esthetic changes, light
sensitivity, and reading difﬁculties were mentioned by both
physicians and patients focus groups.
Table 3 provides a summary of the list of concepts
deemed relevant for incorporation in the questionnaire
empirically divided into three categories: functional lim-
itations, symptoms, and psychosocial factors. Draft items
were revised based on the 25 cognitive interviews leading to
an increase in the number of items, resulting in a 52-item
questionnaire. This questionnaire will be administered in a
future ﬁeld test with 500 or more respondents to evaluate its
reliability and validity.
Patient preference study
Twenty-ﬁve patients (10 male and 15 female) with a median
age of 69 years (range 47–82) participated in one-on-one
interviews [12]. About half (12/25; 48%) were African
American; a third (9/25; 36%) were White; and four parti-
cipants (4/25; 16%) were Asian or another race.
All 25 participants expressed some concerns with their
ability to perform vision-dependent activities, such as
Table 1 Concepts identiﬁed by physician focus group
•Activity limitations: climbing stairs, walking, increased falls,
difﬁculty navigating unfamiliar places
•Night driving
• Loss of depth perception
• Esthetics: sunken eye, looking older
• Light sensitivity
•Reading difﬁculties: decreased reading speeds, difﬁculty perceiving
whole words
•Ocular irritation: dry eyes, foreign body sensation
• Loss of peripheral vision
• Job loss
•Annoyance or anger about having glaucoma
•Worrying about safety and going blind
Underlined text represents categories identiﬁed by both physician and
patients
Table 2 Concepts identiﬁed by patient focus groups
•Activity limitations: tripping and falling when walking, difﬁculty
pouring water into a glass, unable to ski, unable to play basketball,
avoiding putting head below heart when exercising
•Night driving: judging distances, peripheral vision
• Loss of depth perception: “smeared vision”
• Esthetics: drooping eye lid, enlarged eye, hyperpigmentation
• Light sensitivity: need to wear sunglasses
•Reading difﬁculties: needing breaks when reading (or using a
computer)
•Double vision from scarring
•Decreased contrast perception: can’t see a person’s features, losing
golf balls
•Difﬁculty distinguishing colors: dark blue and black, light pink
• Treatment burden: adhering to treatment regimen, nuisance, time
consuming, inconvenience, pain, overwhelming
•Drops: drip down throat, cause blurry vision, make one drowsy,
cause red/bloodshot eyes
Underlined text represents categories identiﬁed by both physician and
patients
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reading and driving. All 25 participants also had an opinion
about intraocular pressure (IOP), and among those currently
taking ocular hypotensive eye drops, all recognized the
relationship between eye drops and IOP. We identiﬁed 13
outcomes that participants perceived as important across
four thematic areas: (1) limitations in performing speciﬁc
vision-dependent activities of daily living (able to read ﬁne
print; drive during the day/at night; and navigate indoors/
outside); (2) problems with visual perceptions (able to
perceive depth; peripheral vision; and seeing in extreme
lighting conditions); (3) treatment burden, including ocular
events (reducing number of pressure lowering drops;
maintaining appearance of the eye; and not experiencing
ocular surface symptoms); and (4) having adequate IOP
control. We designed a preference elicitation survey using
these 13 outcomes.
Of 1035 patients we invited to participate in the pre-
ference elicitation survey, 274 (26%) responded [13]. More
than half of them (146/274, 53%) were older than 65 years
of age and were on IOP-lowering drops (179/274, 65%).
Most of the participants who responded (196/274; 72%)
were White; about 10% (26/274) were African American;
and 52 participants (18%) were Asian or another race.
Participants identiﬁed that outcomes with the largest relative
importance weights were “adequate IOP control” and “drive
a car during the day,” and the outcomes with the smallest
relative importance weights were “maintaining appearance
of the eye” and “reducing the number of IOP-lowering
drops”. Table 4 displays the ranking of the 13 outcomes.
Discussion
It is important that outcomes chosen for glaucoma research
translate into perceived beneﬁts for glaucoma patients. The
next step for evaluating the questionnaire is the ﬁeld test. It
will provide information on the psychometric properties
(reliability and validity) of the questionnaire. We are pur-
suing a partnership with the IRIS® Registry of the American
Academy of Ophthalmology (AAO) and Verana Health.
Verana Health has an ongoing agreement with the AAO that
allows for access to the Registry data. The ﬁnal ques-
tionnaire is expected to be valuable for the advancement of
glaucoma care. While developed to assist in device inno-
vation for patients with mild to moderate OAG, it may also
prove useful for other research studies as well as clinical
applications.
Table 3 Areas to target for the questionnaire
• Functional limitations
Climbing stairs, walking, tripping and falling when walking,
difﬁculty pouring water into glass, impairment in sporting activities,
needing breaks when reading or using a computer, avoiding driving
at night, can’t see whole words and slowing of reading speed, can’t
see a person’s features, and difﬁculty distinguishing colors
• Symptoms
Sensitivity to bright lights, dry, red, bloodshot or irritated eyes,
foreign body sensation, “smeared vision,” and blurry vision
• Psychosocial factors
Job loss, changes in looks (skin, sunken eye, droopy eyelid, looking
older), uncomfortable with unfamiliar places, annoyance or anger
about having glaucoma, and worrying about safety and going blind
Table 4 Outcomes identiﬁed in 25 one-on-one interviews and their relative rankings in preference elicitation survey
Outcome  importance weights (95% CI) 
 -scaled weightsa (95% CI) and Plot Rank 
Have control of intraocular pressure 1.28 ( 1.09  to  1.47)  14.8%  (13.5% to 16.0%)  1st 
Drive a car during the day 1.22 ( 1.06  to  1.39)  14.4% (13.3% to 15.5%)  2nd 
dr3)%7.11ot%9.9(%8.01)28.0ot55.0(86.0emohehtedistuoytilibomniatniaM
Maintain mobility inside the home 0.61 ( 0.46  to  0.76)  10.3% (  9.3% to 11.3%)  4th 
ht5)%9.9ot%4.8(%1.9)45.0ot93.0(24.0htpedeviecreP
ht6)%8.9ot%5.7(%6.8)35.0ot41.0(33.0thgintaracaevirD
ht7)%1.8ot%3.6(%2.790.0tnirpenifdaeR
See in very dim or very bright light –0.03    6.6% (  5.9% to   7.3%)  8th 
No ocular surface symptoms –0.21 (–0.37  to –0.05)
(–0.17  to  0.10)
(–0.08  to  0.26)
   5.8% (  5.1% to   6.5%)  9th 
See things oﬀ to the side (peripheral vision) –0.36 (–0.46  to –0.26)    5.1% (  4.7% to   5.5%)  10th 
ht11)%5.4ot%6.3(%0.4–0.65rolochsiugnitsiD
Reduce number of IOP lowering drops –1.57 (–1.76  to –1.38)     1.8% (  1.4% to   2.1%)  12th 
Maintain appearance of the eye (cosmesis) –1.81 (–2.00  to –1.62)
(–0.78  to –0.51)
    1.4% (  1.2% to   1.7%)  13th 
CI conﬁdence interval, IOP intraocular pressure
*Weights are ratio scaled using a probability-based rescaling procedure: ratio-scaled weight= eUi/(eUi+ a−1), where eUi is the antilog of the zero-
centered coefﬁcient for item i and a is the number of items shown per choice set. A preference weight of 10% is twice as preferred as an outcome
with a preference weight of 5%
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The outcomes identiﬁed as important by patients from
the patient preference study are congruent with those
identiﬁed in the questionnaire. A sample of participants
across the country prioritized control of IOP and the ability
to drive as the most important outcomes. They also
expressed that the ability to perform other vision-dependent
activities (e.g., navigating inside/outside the house) and
maintaining visual perceptions (e.g., depth perception) are
more important than burden of treatment (e.g., number of
IOP-lowering drops). Many of the outcomes that partici-
pants deemed as most important to them are not outcomes
that have been measured consistently in MIGS studies [8].
Patients have the potential to steer clinical research
activity towards outcomes important to them. Historically,
clinical trials are designed to demonstrate efﬁcacy in an
experimental context using design features that aim for
rapid and clear answers. Surrogate measures and biomarkers
are widely used because they are thought to have feasibility
advantages. But surrogate measures such as IOP alone are
not always in the interest of patients because of concerns
about applicability to clinical practice. It is possible that
patients have been led by their healthcare providers to place
an undue emphasis on IOP control - that IOP is “not of
concern to patients until they have been educated, or rather
miseducated, to believe that there are linear relationships”
between eye pressure and what the patient can do or how
well they feel [16]. Future studies could explore this
hypothesis by recruiting only treatment naïve participants.
Ideally, incorporation of outcomes that capture func-
tioning, well-being, treatment burden, and visual percep-
tions from patients’ point of view are considerations for
future MIGS clinical trials. Incorporating the patients’ per-
spectives into the MIGS device development and evaluation
process may expedite innovation and availability of these
devices and inform patient and healthcare provider decision
making on treatments.
Summary
What was known before
● Despite many therapeutic options available for patients
with mild to moderate open angle glaucoma, it is unclear
how patients view different treatments and which
patient-reported outcomes would be most relevant
for them.
What this study adds
● Incorporation of outcomes that capture functioning,
well-being, treatment burden, and visual perceptions
from patients’ point of view are considerations for future
clinical trials in glaucoma.
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